Urologie Vaterstetten - Dr. med. Block, Vaterstetten
Urologie Vaterstetten - Dr. med. Block, Vaterstetten Urologie Vaterstetten - Dr. med. Block, Vaterstetten
84. Mallick S, Azzouzi R, Bey P, Cormier L, Moreau JL, Peiffert D, Mangin P: Acute urinary complications after prostate iodine-125 brachytherapie: evaluation and risk factors. Cancer Radioth 6:99-105, 2002 85. Mangili P, Longobardi B, Di Muzio N, Nava L, Losa A, Guazoni G: Importance of diagnostic modality in post planning dosimetric analysis of permanent prostate brachytherapy. Rad Oncol 32, 2001 86. Marion PR, Van Gellekom MSc, Moerland MA, Kal HB, Battermann JJ: Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema. Int J Rad Oncol Biol Phys 53:, 422-433, 2002 87. Martini N, Hilaris BS, Nori D (eds): Clinical application of interstitial implantation in carcinoma of the lung. New York, Memorial Sloan-Kettering Cancer Center Brachytherapy 23-27, 1984 88. Maurer U, Block T, Mulhern AD: Optimization of seed implantation with interactive TRUSonline-dosimetry in patients with prostate cancer. Radiology, 221 (Suppl):178, 2001 89. Maurer U, Eble MJ: The technique of 125-Jod permanent implants. Front Radiat Ther Oncol 36: 159-165, 2002 90. Merrick G, Butler W, Galbreath R, Lief J, Adamovich E: Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confirmed carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys 52:664-673, 2002 91. Merrick G, Butler W, Lief J: Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 51:41-48, 2001 92. Merrick G, Butler W, Lief J, Galbreath RW: : Five-year biochemical outcome after prostate brachytherapy for hormone naïve men < or = 62 years of age. clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 50:41-48, 2001 93. Merrick GS, Butler WM, Dorsey AT,Galbreath RW, Blatt H, Lief JH: Rectal function following prostate brachytherapy. Int J Rad Oncol Biol Phys 48:667-674, 2000 94. Merrick GS, Butler W, Lief J, Dorsey A: Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47:121–128, 2000 95. Merrick GS, Wallner K, Butler W, Lief J, Sutlief S: Short-term sexual function after prostate brachytherapy. Int J Cancer 96:313–319, 2001 96. Merrick GS, Wallner K, Butler W, Galbreath R, Lief J, Benson M: A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy included erectile dysfunction. Int J Radiat Oncol Biol Phys 50:597-604, 2001 97. Merrick GS, Butler W, Dorsey A, Lief J, Benson M: Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 46:215–220, 2000 98. Merrick GS,Butler WM, Lief JH, Dorsey AT: Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer? Tech Urol 7:12-19, 2001 99. Miller, K; Weißbach, L. (Herausg.): Leitlinien zur Diagnostik von Prosttakarzinomen. Urologe A 38:388 –401, 1999 100. Morton JD, Peschel RE:Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer. Int J Radiat Oncol Biol Phys 14:1153–1157, 1988 85
101. Nag S, Bice W, De Wyngaert K, Prestidge B, Stock R, Yu Y: The American Brachytherapy Society recommendations for permanent prostate brachytherapy: Postimplant dosimetric analysis. Int J Rad Oncol Biol Phys 46: 221-230, 2000 102. Nag S, Beyer D, Friedland J, Grimm P, Nath R: American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44: 789–799, 1999 103. Nag S, Ciezki JP, Cormack R, Doggett S, De Wyngaert K, Edmundson GK, Stock RG, Stone NN, Yu Y, Zelefsky MJ: Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American brachytherapy society. Int J Rad Oncol Biol Phys 51:1422-1430, 2001 104. Nath R, Meigoom AS, Meli JA: Dosimetry of the transverse axes of 125 I and 192 Ir interstitial brachytherapy sources. Med Phys, 17:1032-1040, 1990 105. Nath R, Roberts K, Nag M: Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants Med Phys 25:2293–2307, 1998 106. Neglia WJ, Hussey DH, Johnson DE: Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2:873–883, 1977 107. O'Leary MP, Baum NH, Blizzard R, Blute ML, Cooper TP, Dineen MK, Fenninger R, Gee WF, Gormley EA, Ignatoff JM, Nachtsheim DA, Painter MR, Thomas R, Wei JT For The Health Policy Survey and Research Committee: 2001 American Urological Association Gallup Survey: Change in physician practic patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol 168:649-652, 2002 108. Partin A, Mangold L, Lamm D, Walsh P, Epstein J Pearson J: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. J Urol 58:843– 848, 2001 109. Peller P, Young D, Marmaduke D, Marsh W, Badalament R: Sextant prostate biopsies: A histopathologic correlation with radical prostatectomy specimens. Cancer 75:530–538, 1995 110. Penson DF: Quality of life following prostate cancer treatments. Curr Urol Rep 1:71-77, 2000 111. Perez CA, Walz BJ, Zivnuska FR: Irradiation of carcinoma of the prostate localized to the pelvis: Analysis of tumor response and prognosis. Int J Radiat Oncol Biol Phys 6: 555–563, 1980 112. Pickett B, Fisch B, Weinberg V Roach M: Dose to the bulb of the penis is associated with the risk of impotence following radiotherapy. Int J Radiat Oncol Biol Phys 45 (suppl): 263, 1999 113. Pinkawa M, Maurer U, Mulhern A, Gagel B, Eble MJ, Block T: Wertigkeit der inversen Bestrahlungsplanung mit unterschiedlichen Aktivitäten bei der interstitiellen Brachytherapie des Prostatakarzinoms. Strahlentherapie und Onkologie, 177: 67, 2001 114. Pollack A, Smith LG, von Eschenbach AC: External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48: 507–512, 2000 115. Pollack A, Zagars GK, Smith LG: Preliminary results of a randomized radiotherapy doseescalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904– 3911, 2000 86
- Seite 37 und 38: 9.2 Inkontinenz: Abb. 18: D1 Urethr
- Seite 39 und 40: 9.3 Erektile Potenz: Die Betrachtun
- Seite 41 und 42: Radioisotop keine erektile Dysfunkt
- Seite 43 und 44: 9.3.1 Eigenes Patientenkollektiv: 7
- Seite 45 und 46: Tapen et al. (141) untersuchten die
- Seite 47 und 48: Percent with PSA spike 100% 75% 50%
- Seite 49 und 50: Fragen zum Vergleich mit anderen Me
- Seite 51 und 52: 10.2 Perkutane Strahlentherapie: Di
- Seite 53 und 54: Es gibt aus der Vergangenheit einig
- Seite 55 und 56: 10.3 Zuordnung des Patienten zu ein
- Seite 57 und 58: 11. Wie ist die Wirksamkeit der per
- Seite 59 und 60: Die alleinige permanente Seedimplan
- Seite 61 und 62: 140 135 130 125 120 115 FACT-P by T
- Seite 63 und 64: 12. Werden durch den Einsatz der pe
- Seite 65 und 66: Abb. 36: Uniforme Beladung mit hoch
- Seite 67 und 68: 13.2 Modifizierte periphere Beladun
- Seite 69 und 70: 15. Welche diagnostischen und thera
- Seite 71 und 72: 16. Sind die Patienten zur Durchfü
- Seite 73 und 74: 17.3 Technische Voraussetzungen: Al
- Seite 75 und 76: 19. Wie hoch sind die unmittelbaren
- Seite 77 und 78: 21. Welche Kosten könnten durch de
- Seite 79 und 80: Ergänzungen: 22. Gibt es zusätzli
- Seite 81 und 82: Abb. 44: CT-Nachplanung und korresp
- Seite 83 und 84: Literaturverzeichnis 1. Albertsen P
- Seite 85 und 86: 32. Critz FA, Williams WH, Benton J
- Seite 87: 66. Hilaris BS,Martini N. The curre
- Seite 91 und 92: 133. Shipley WU, Nardi GL, Cohen AM
101. Nag S, Bice W, De Wyngaert K, Prestidge B, Stock R, Yu Y: The American Brachytherapy<br />
Society recommendations for permanent prostate brachytherapy: Postimplant dosimetric<br />
analysis. Int J Rad Oncol Biol Phys 46: 221-230, 2000<br />
102. Nag S, Beyer D, Friedland J, Grimm P, Nath R: American Brachytherapy Society (ABS)<br />
recommendations for transperineal permanent brachytherapy of prostate cancer. Int J<br />
Radiat Oncol Biol Phys 44: 789–799, 1999<br />
103. Nag S, Ciezki JP, Cormack R, Doggett S, De Wyngaert K, Edmundson GK, Stock RG,<br />
Stone NN, Yu Y, Zelefsky MJ: Intraoperative planning and evaluation of permanent<br />
prostate brachytherapy: Report of the American brachytherapy society. Int J Rad Oncol<br />
Biol Phys 51:1422-1430, 2001<br />
104. Nath R, Meigoom AS, Meli JA: Dosimetry of the transverse axes of 125 I and 192 Ir<br />
interstitial brachytherapy sources. Med Phys, 17:1032-1040, 1990<br />
105. Nath R, Roberts K, Nag M: Correlation of <strong>med</strong>ical dosimetry quality indicators to the local<br />
tumor control in patients with prostate cancer treated with iodine-125 interstitial implants<br />
Med Phys 25:2293–2307, 1998<br />
106. Neglia WJ, Hussey DH, Johnson DE: Megavoltage radiation therapy for carcinoma of the<br />
prostate. Int J Radiat Oncol Biol Phys 2:873–883, 1977<br />
107. O'Leary MP, Baum NH, Blizzard R, Blute ML, Cooper TP, Dineen MK, Fenninger R, Gee<br />
WF, Gormley EA, Ignatoff JM, Nachtsheim DA, Painter MR, Thomas R, Wei JT For The<br />
Health Policy Survey and Research Committee: 2001 American Urological Association<br />
Gallup Survey: Change in physician practic patterns, satisfaction with urology, and<br />
treatment of prostate cancer and erectile dysfunction. J Urol 168:649-652, 2002<br />
108. Partin A, Mangold L, Lamm D, Walsh P, Epstein J Pearson J: Contemporary update of<br />
prostate cancer staging nomograms (Partin Tables) for the new millennium. J Urol 58:843–<br />
848, 2001<br />
109. Peller P, Young D, Marmaduke D, Marsh W, Badalament R: Sextant prostate biopsies: A<br />
histopathologic correlation with radical prostatectomy specimens. Cancer 75:530–538,<br />
1995<br />
110. Penson DF: Quality of life following prostate cancer treatments. Curr Urol Rep 1:71-77,<br />
2000<br />
111. Perez CA, Walz BJ, Zivnuska FR: Irradiation of carcinoma of the prostate localized to the<br />
pelvis: Analysis of tumor response and prognosis. Int J Radiat Oncol Biol Phys 6: 555–563,<br />
1980<br />
112. Pickett B, Fisch B, Weinberg V Roach M: Dose to the bulb of the penis is associated with<br />
the risk of impotence following radiotherapy. Int J Radiat Oncol Biol Phys 45 (suppl): 263,<br />
1999<br />
113. Pinkawa M, Maurer U, Mulhern A, Gagel B, Eble MJ, <strong>Block</strong> T: Wertigkeit der inversen<br />
Bestrahlungsplanung mit unterschiedlichen Aktivitäten bei der interstitiellen Brachytherapie<br />
des Prostatakarzinoms. Strahlentherapie und Onkologie, 177: 67, 2001<br />
114. Pollack A, Smith LG, von Eschenbach AC: External beam radiotherapy dose response<br />
characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol<br />
Biol Phys 48: 507–512, 2000<br />
115. Pollack A, Zagars GK, Smith LG: Preliminary results of a randomized radiotherapy doseescalation<br />
study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904–<br />
3911, 2000<br />
86
Change language